Research Behind Sustained Acoustic Medicine Journals and Conferences


1. Jarit et al. 2023 “Long Duration Sonophoresis of Diclofenac to Augment Rehabilitation of Common Musculoskeletal Injuries.” Glob J Ortho Res. 4(2): 2023.
2. Krystofiak et al 2023 “Long Duration Ultrasound Combined with Platelet-Rich Plasma Injection for Return to Sport after Soft Tissue Injury”. Orthop Muscular Syst.1.
3. Winkler et al. 2021 “Sustained acoustic medicine for the treatment of musculoskeletal injuries: a systematic review and meta-analysis.” BMC Sports Science, Medicine and Rehabilitation (2021)
4. Uddin et al. 2021 “Low-Intensity Continuous Ultrasound Therapies—A Systemic Review of Current State-of-the-Art and Future Perspectives.” Journal of Clinical Medicine (2021).
5. Best et al. 2020 “Sustained acoustic medicine as a nonsurgical and non-opioid knee osteoarthritis treatment option: a health economic cost effectiveness analysis for symptom management.” Journal of Orthopaedic Surgery and Research (2020)
6. Best et al. 2016 “Low Intensity Ultrasound for Promoting Soft Tissue Healing: A Systematic Review of the Literature and Medical Technology.” Intern Med Rev (Wash D C)
7. Patterson et al. 2020 “Low-Intensity Continuous Ultrasound for the Symptomatic Treatment of Upper Shoulder and Neck Pain: A Randomized, Double-Blind Placebo-Controlled Clinical Trial.” J. Pain Reas. 2020
8. Draper et al. 2018 “Effect of low-intensity long-duration ultrasound on the symptomatic relief of knee osteoarthritis: a randomized, placebo-controlled double-blind study.” J. Orth. Surg. Reas. 2018
9. Langer et al. 2015 “Sustained acoustic medicine provides pain relief for osteoarthritis of the knee.” Physiotherapy, 101, e864.

Technology History

A significant and growing body of +40 basic science, animal and human subject clinical research studies support the sam® family of ultrasound products FDA approvals, indications and clinical outcomes achieved for patients. Over 20 level I-V clinical research studies, randomized-placebo-controlled trials and publications on back pain, arthritis pain, strain injuries of tendons and ligaments, recovery, range of motion, strength and the healing of soft tissue have been published on ZetrOZ Technology. Additional clinical health economic studies have demonstrated that sam® treatment saves over $27,000.00 in medical and indemnity expenses when introduced early into the treatment program of an injured patient. sam® is clinically proven to treat the underlying cause of pain, reduce healthcare costs and the risks associated surgery and medication. Additionally, sam® has proven to return patients to work with elbow and shoulder injuries to maximum medical improvement (MMI) in 8-weeks, and 10-weeks for lower-back injuries.

Over a decade ago the precursor of sam® medical technology was evolving out of a biomedical research laboratory in the founders lab. Since FDA approval in 2014, sam® has already helped over 200,000 patients in the United States. This has been made possible by the support of US Governmental agencies including the National Institutes of Health, the Department of Defense, the National Science Foundation, the National Space Biomedical Research Institute, the National Arthritis Foundation and University and Industry partners who have funded millions of dollars of research into the sam® family of ultrasound products. sam® is currently being used by thousands of athletes, soldiers and chronic pain suffers, and is covered by health insurance for the military and veterans, professional, Olympic and college athletes, and people injured in accidents on and off the job. There is growing awareness and our company BHAG is to help 100 million people with sam® technology and research.

Clinical Research Summary 2019

picture 1

Long Duration Ultrasound Innovation